Duke logo

Medicenna MDNA55-05 (Glioblastoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug MDNA55 is safe and will work in patients with glioblastoma brain tumors when given directly into the brain.

What is the Condition Being Studied?

Glioblastoma

Who Can Participate in the Study?

Adults who:
- Have a confirmed diagnosis of a first or second recurrence of glioblastoma brain cancer
- Have no prior treatment with the drug Bevacizumab (Avastin)

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Have the study drug MDNA55 given directly into your brain tumor through thin tubes called catheters that are surgically placed within the tumor.
- Stay in the hospital for at least 24 hours after the drug is given for tests and observations
- Return to the clinic for follow-up visits 2 weeks after you leave the hospital and at least 1 time per month for up to 12 months after the study drug is given

Study Details

Full Title
MDNA55-05: An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection Enhanced Delivery (CED) of MDNA55 in Adults with Recurent or Progressive Glioblastoma
Principal Investigator
Neuro-oncologist
Protocol Number
IRB:PRO00076523
NCT:NCT02858895
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698